Literature DB >> 2439842

Stereoselective effects of disopyramide enantiomers in humans.

J J Lima, H Boudoulas.   

Abstract

The effects of 100 mg of (S+)- and R(-)-disopyramide infused over 20 min on systolic time intervals and the QT interval were compared in five healthy volunteers. S(+)-disopyramide maximally prolonged the QTI (QT corrected for heart rate) by 10% (p less than 0.05); R(-)-disopyramide had no effect on QTI. R(-)-disopyramide maximally prolonged the preejection period and shortened the left ventricular ejection time corrected for heart rate (PEPI and LVETI), and increased the ratio of PEP/LVET by 32, 6, and 52%, respectively; S(+)-disopyramide maximally increased PEPI and PEP/LVET 15 and 20%, respectively (p less than 0.05), and had no effect on LVETI. These data suggest that the electrophysiologic effects of disopyramide enantiomers are different, and that S(+)-disopyramide has a less negative inotropic effect than R(-)-disopyramide. Changes in response were fitted to a pharmacokinetic-pharmacodynamic model, which estimated that 72% of the negative inotropic effects associated with racemic disopyramide may be avoided by using S(+)-disopyramide.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2439842     DOI: 10.1097/00005344-198705000-00014

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  9 in total

Review 1.  Antiarrhythmics--from cell to clinic: past, present, and future.

Authors:  J C Hancox; K C Patel; J V Jones
Journal:  Heart       Date:  2000-07       Impact factor: 5.994

Review 2.  Therapeutic drug monitoring of antiarrhythmic drugs.

Authors:  Gesche Jürgens; Niels A Graudal; Jens P Kampmann
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 3.  Impact of stereoselectivity on the pharmacokinetics and pharmacodynamics of antiarrhythmic drugs.

Authors:  Reza Mehvar; Dion R Brocks; Majid Vakily
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 4.  Nonlinear pharmacokinetics: clinical Implications.

Authors:  T M Ludden
Journal:  Clin Pharmacokinet       Date:  1991-06       Impact factor: 6.447

Review 5.  Pharmacokinetic-pharmacodynamic modeling in the data analysis and interpretation of drug-induced QT/QTc prolongation.

Authors:  Vladimir Piotrovsky
Journal:  AAPS J       Date:  2005-10-24       Impact factor: 4.009

6.  Effects of the enantiomers of disopyramide and its major metabolite on the electrophysiological characteristics of the guinea-pig papillary muscle.

Authors:  F Vanhoutte; J Vereecke; E Carmeliet; N Verbeke
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1991-12       Impact factor: 3.000

7.  Stereoselective pharmacokinetics of disopyramide and interaction with cimetidine.

Authors:  J Bonde; L E Pedersen; E Nygaard; T Ramsing; H R Angelo; J P Kampmann
Journal:  Br J Clin Pharmacol       Date:  1991-06       Impact factor: 4.335

8.  Inhibition of the current of heterologously expressed HERG potassium channels by flecainide and comparison with quinidine, propafenone and lignocaine.

Authors:  Ashok A Paul; Harry J Witchel; Jules C Hancox
Journal:  Br J Pharmacol       Date:  2002-07       Impact factor: 8.739

9.  Differential binding of disopyramide and warfarin enantiomers to human alpha(1)-acid glycoprotein variants.

Authors:  T Nakagawa; S Kishino; S Itoh; M Sugawara; K Miyazaki
Journal:  Br J Clin Pharmacol       Date:  2003-12       Impact factor: 4.335

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.